BiotechTube

mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urinary Bladder Diseases

Conditions

Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases

Trial Timeline

Jul 10, 2013 → Nov 25, 2014

NCT ID
NCT01908829

About mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placebo

mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placebo is a phase 3 stage product being developed by Astellas Pharma for Urinary Bladder Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT01908829. Target conditions include Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01908829Phase 3Completed

Competing Products

20 competing products in Urinary Bladder Diseases

See all competitors
ProductCompanyStageHype Score
Duloxetine + placeboEli LillyPhase 2
52
DuloxetineEli LillyPhase 2
52
Enfortumab vedotinAstellas PharmaPhase 1
33
solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
85
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
52
SolifenacinAstellas PharmaApproved
85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
77
Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
85
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaPre-clinical
23
TamuslosinAstellas PharmaPhase 3
77
Tamsulosin + SolifenacinAstellas PharmaApproved
85
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
85
solifenacin succinate + tolterodineAstellas PharmaPhase 3
77
TamusulosinAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
77
Solifenacin succinate + PlaceboAstellas PharmaPhase 3
77
VesicareAstellas PharmaPre-clinical
23

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85